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Abstract 
 
Objective: There are no consistent data on the prevalence and bone status for normocalcemic 
hypoparathyroidism (NHYPO) as defined by normal adjusted calcium and low PTH level. Our aim is to 
determine the prevalence and the bone metabolic profile of NHYPO in older women assessing its 
evolution over the time. The second objective is to evaluate the prevalence of the other calcium 
metabolic disorders. 
 
Design: The Osteoporosis and Ultrasound Study (OPUS) is a 6-yr prospective study of fracture-
related factors. 
 
Participants: a total of 2419 older women (ages 55-79) and 258 younger women (ages 30-40) 
participated. Complete follow-up data are available in 1416 subjects. 
 
Measurements PĨƚĞƌĐĂůĐƵůĂƚŝŶŐƚŚĞĂĚũƵƐƚĞĚĐĂůĐŝƵŵĂĐĐŽƌĚŝŶŐƚŚĞ:ĂŵĞƐ ?ƐĨŽƌŵƵůĂ ?ǁĞŝĚĞŶƚŝĨŝĞĚ
the  ?ĂďŶŽƌŵĂů ?ĐĂůĐŝƵŵĂŶĚWd,ƵƐŝŶŐDĂŚĂůĂŶŽďŝƐŝƐƚĂŶĐĞƐĂŶĚǁĞĂůůŽĐĂƚĞĚŽůĚĞƌǁŽŵĞŶŝŶƚŽ
different pathological categories using reference intervals from the healthy young women. 
 
Results: We identified 57 subjects with NHYPO (2.4%). These women have lower than expected 
bone turnover as assessed by bone alkaline phosphatase (-14.5%, 95% CI: -26.2 to -3.0, p=0.007), 
CTX (-66.3%, 95% CI: -74.0 to -56.4, p<0.001) and osteocalcin (-36.8%, 95% CI: -45.6 to -26.6, 
p<0.001). After 6 years, of the 35 NHYPO subjects with follow-up data, none developed overt 
hypoparathyroidism and only 15 (0.6%) subjects had persistent evidence of NHYPO. We also 
identified 86 subjects (3.6%) affected by hyperparathyroid hypercalcemia. 
 
Conclusion: This is the first large population-based study that has investigated NHYPO in older 
women. It is fairly common, not always persistent and is characterized by low bone turnover. 
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Background 
Parathyroid hormone (PTH) is the major hormonal mediator of extracellular calcium homeostasis 
and regulates osteoclastic bone resorption, the renal excretion of calcium and synthesis of 1,25-
dihydroxyvitamin D. Circulating PTH concentrations display a large inter-individual variability and this 
variance has been demonstrated to have a strong hereditable component (1). However, the genetic 
factors governing serum PTH concentrations remain to be elucidated. PTH is an 84 amino-acid 
peptide, whose secretion by the parathyroid chief cells is regulated by the calcium-sensing receptor 
(CaSR), which is expressed at the parathyroid cell-surface. Mutations of the CaSR gene lead to 
inherited forms of hypercalcaemia and hypocalcaemia (2), and common coding region CaSR single 
nucleotide polymorphisms (SNPs) have been revealed as determinants of serum calcium 
concentrations (3). Cusano and colleagues recently reported the prevalence of normocalcemic hyper 
(NPHPT) and hypoparathyroidism (NHYPO) in two unselected, non-referral community-dwelling 
populations identifying a prevalence of 0.4 - 3.1% and 1.1 - 1.9% respectively (4). NPHPT is 
characterized by normal calcium levels with high PTH in the absence of secondary causes of 
hyperparathyroidism (5) and it was officially recognized by the Third International Workshop on the 
Management of Asymptomatic Primary Hyperparathyroidism (6). These patients may develop a 
similar rate of low bone mineral density compared to subjects with primary hyperparathyroidism 
(PHPT) (7) and it seems that there is a trend toward a higher recurrence of NPHPT after 
parathyroidectomy (8).  
 
While NPHPT is a well-documented diagnostic category, no consistent data are available for NHYPO. 
The diagnosis of NHYPO has been used for patients who develop hypocalcaemia in response to 
bisphosphonate therapy having had normal calcium values and low PTH levels prior to starting 
therapy; such patients were considered to have inadequate parathyroid gland reserve (9). We 
cannot yet be certain whether NHYPO is a real diagnostic category. Indeed Cusano and colleagues 
identified 68 subjects with NHYPO, none of whom developed overt hypoparathyroidism on follow-up 
and persistent disease was noted in 2 of 26 subjects that concluded the follow-up period (4).  
 
It is possible that the prevalence of NHYPO by Cusano and colleagues (4) may have underestimated 
the prevalence in the general population because they only studied men and young women. It is 
important to study older women as many parathyroid diseases such as PHPT have their peak 
incidence in the first decade after the menopause (10-12).  
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The primary end point of this study is to determine the prevalence and the bone metabolic profile of 
NHYPO in our population assessing its evolution over the time. The secondary endpoint is to 
evaluate the prevalence of the other calcium metabolic disorders. 
 
Materials and methods 
Study deign and population 
We recruited 2419 older women (ages 55-79) and 258 younger women (ages 30-40) from 5 
European cities (the OPUS study) (13). The OPUS study is a large population-based cohort study 
designed to determine quantitative ultrasound (QUS) performance in direct comparison with central 
DXA. The design of the Osteoporosis and Ultrasound (OPUS) study has previously been reported 
(13). In particular exclusion criteria were limited to disorders that precluded valid QUS 
measurements (i.e., bilateral fractures of the calcaneus, bilateral hip prostheses, disorder of the 
hand), general inability to undergo the specified exams, and cognitive limitations that preclude filling 
out self-administered questionnaires. Pregnant women were excluded because of potential risks 
associated with X-ray exposure. All investigations were conducted in accordance with the 
Declaration of Helsinki. Ethical approval was obtained from the local ethics committees and written 
informed consent was obtained from each subject. 
 
The OPUS study became a longitudinal study when laboratory and other data were collected 
approximately 6 years later and complete follow-up data are available in 1416 subjects. Each subject 
had a first visit  (between 1999-2001) and then 6 years later was invited to attend for a second visit 
(between 2005-2007). At the time of each study visit a modified version of the European Vertebral 
Osteoporosis Study (EVOS) risk factor questionnaire (14) was administered to each subject. From 
this we were able to collect medical and lifestyle information. Medical history of diseases and 
treatments was recorded. Non-fasting venous blood samples were collected from each subject 
between 12:00 and 15:00 into serum separating tubes. The blood was left to clot for 30 minutes at 
room temperature and centrifuged at 2500 g for 10 minutes. The serum was then collected and 
stored at -80°C until analysis. Second morning void urine samples were collected and stored at -20°C 
until analysis. 
 
To estimate reference intervals for adjusted calcium and PTH, 107 young women were eligible after 
excluding those with low 25-hydroxyvitamin D (25OHD) (< 20 ng/ml), eGFR < 60 ml/min per 1.73m² , 
T-score at lumbar spine or total hip equal to or less than -2.5 and those taking drugs or suffering 
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from diseases known to affect bone (Table 1). Both adjusted serum calcium and PTH were log10 
transformed prior to analysis. 
 
Biochemical measurements 
Blood samples were drawn to measure serum: 
 
- Calcium and albumin. They were measured using the Cobas c701 (Roche Diagnostics, Germany) 
auto analyser in the Chemical Pathology laboratory, Sheffield Teaching Hospitals, UK. The 
ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛreported inter assay precision is <2.0% for each test. We calculated adjusted calcium 
in all subjects (pre- and post-menopausal women were included in the analysis) based on the total 
calcium and albumin ŵĞĂƐƵƌĞŵĞŶƚƐĂĐĐŽƌĚŝŶŐƚŽ:ĂŵĞƐ ?ƐĨŽƌŵƵůĂ ? ? ? ?ĂŶĚ ?ĂƐƌĞĐŽŵŵĞŶĚĞĚŝŶƚŚat 
report) we excluded subjects with creatinine > 200 and/or albumin <20 g/L or 50 g/L > and/or total 
calcium >3 mmol/L. In particular, at baseline, 2638 women were included in the analysis and the 
local adjustment equation was expressed by the following relationship: adjusted Calcium = Total 
Calcium - (0.015 x albumin) + 0.699. After six years follow up (1652 women were included in the 
analysis), the local adjustment equation was expressed by the following relationship: adjusted 
Calcium = Total Calcium - (0.018 x albumin) + 1.581 
 
- Collagen type 1 cross-linked C-telopeptide (CTX), intact procollagen type 1 N propeptide (PINP), 
bone alkaline phosphatase (bone ALP), 25OHD and PTHi. They were measured in serum using the 
IDS-iSYS automated immunoassays (Immunodiagnostic Systems, Boldon, United Kingdom). 185 The 
inter assay coefficients of variation (CV) were 6.5%, 7.2%, 3.5%, 6.7% and 6.5% respectively. 
 
- Creatinine. It was measured using the Cobas c 311automated analyser (Roche Diagnostics, 
Germany). This was used to calculate the estimated glomerular filtration rate (eGFR) using the 
formula based on the modification of diet and renal disease (MDRD) (16) 
 
We measured the samples from baseline and 6 years at the same time. 
 
Bone densitometry 
At both visits, bone mineral density (BMD) was performed using dual-energy X-ray absorptiometry 
(DXA) of the lumbar spine and the proximal femur in posteroanterior projection (Hologic QDR-4500; 
Hologic, Bedford, MA, USA in the Kiel, Paris, and Sheffield centers) or in anterior-posterior projection 
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(Lunar Expert devices; GE Lunar, Madison, WI, USA in the Aberdeen and Berlin centers). 
Measurements were standardised and cross calibrated across centres. 
 
Statistical analysis 
To classify the abnormalities of calcium homeostasis, we used the following approach: 
 
-We calculated adjusted calcium in all subjects based on the total calcium and albumin 
measurements (see above); 
 
- Reference intervals were calculated for adjusted serum calcium and PTH using data from the 
healthy pre-menopausal women. Both adjusted serum calcium and PTH were log10 transformed 
prior to analysis and the mean +/- 1.96SD calculated (Table 1). 
 
-We allocated older women (baseline) into one of eight categories by using the ellipse defined by the 
Mahalanobis Distance Analysis (Figure 1) which measure how far each observation is from the 
center of a data cluster, taking into account the shape of the cluster. Observations are considered 
outliers if MD² > ߯ଶǢ଴Ǥଽ଻ହଶ  = 7.378.  tĞƌĞĨĞƌƚŽ ?ŚŝŐŚŽƌůŽǁ ?ŝĨƚŚĞǇĂƌĞŽƵƚƐŝĚĞƚŚĞĞůůŝƉƐĞĂŶĚŚĂǀĞ
values above or below ƚŚŽƐĞĨŽƵŶĚŝŶƚŚĞǇŽƵŶŐǁŽŵĞŶ ?tĞƌĞĨĞƌƚŽ ?ŚŝŐŚŽƌůŽǁŶŽƌŵĂů ?ŝĨƚŚĞǇĂƌĞ
outside the ellipse and have values above or below the mean found in the young women but within 
the reference interval. 
 
- Normal. Anyone inside the ellipse, at baseline; 
- Hyperparathyroid hypercalcemia (HH) that includes both PHPT and familial hypocalciuric 
hypercalcemia (FHH). Anyone outside the ellipse with high adjusted calcium and high or high 
normal PTH; 
- NPHPT. Anyone outside the ellipse with normal adjusted calcium, high PTH, 25OHD > 
20ng/ml and eGFR > 60 ml/min. 
- Secondary hyperparathyroidism. Anyone outside the ellipse with low adjusted calcium and 
high-normal PTH, low adjusted calcium and high PTH, low-normal adjusted calcium and high 
PTH, high-normal adjusted calcium and high PTH with 25OHD < 20ng/ml or/and eGFR < 60 
ml/min; 
- Hypoparathyroidism. Anyone outside the ellipse with low adjusted calcium and low or low 
normal PTH; 
- NHYPO. Anyone outside the ellipse with normal adjusted calcium and low PTH; 
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- Non-PTH hypercalcaemia. Anyone outside the ellipse with high adjusted calcium with low 
or low normal PTH; 
- Missing data patients. Anyone with missing calcium, PTH, or albumin measurements. 
 
We applied the same Mahalanobis Distance Analysis for the older women at follow up (figure 2). In 
this analysis subjects were included if they had measurements for PTH, calcium and albumin at 
baseline and follow-up (N = 1416). 
 
Descriptive statistics 
Characteristics of the subjects were summarized using frequencies and percentages for categorical 
variables. For continuous variables, mean and standard deviation were calculated. Characteristics 
were compared between groups using ANOVA. Post-hoc tests compared all groups to the Normal 
group using the Dunnett method. All measurements with a skewed distribution were log10 
transformed prior to analysis and differences between groups were back transformed and expressed 
as a percentage difference. We have performed a multiple regression analyses looking at the 
relationship between measurements at  “ďĂƐĞůŝŶĞ ?ĂŶĚDd-score at baseline; measurements at 
baseline and change in BMD from baseline 238 to year 6. We have examined the change in PTH 
measurement from baseline to 6 years in the overall population using a paired t-test. The ɲ-level 
was set at 0.05. 
 
Results 
Subject characteristics 
The subject characteristics at baseline are shown in table 2a, table 2b. 
 
Diagnostic categories according to calcium metabolism disorders at baseline 
We have identified (Tables 3 and 4): 
 
- 2063 subjects (85.3%) with no calcium abnormalities: normal adjusted calcium levels (2.4 mmol/L, 
95% CI 2.39 - 2.41) with normal PTH (39 ng/L, 95% CI 38.4  W 39.7); 
 
- 86 subjects (3.6%) affected by HH: high calcium levels (2.79 mmol/L, 95% CI 2.78  W 2.80) with 
elevated PTH (58.80 ng/L, 95% CI 52.6  W 65.8). At the second visit (after 6 years), of the 56 HH 
subjects with follow-up data, 47 (2%) subjects had persistent evidence of HH. 
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- 1 subject (0.1%) affected by NPHPT. At the second visit no subjects met the diagnostic criteria for 
the normocalcemic hyperparathyroidism. 
 
- 69 subjects (2.8%) subjects affected by secondary hyperparathyroidism: low calcium (2.16 mmol/L, 
95% CI 2.09  W 2.23) with high or high normal PTH (88.9 ng/L, 95% CI 75.8  W 104.3). 
 
- 3 subjects (0.1%) affected by hypoparathyroidism; 
 
- 57 subjects (2.4%) affected by NHYPO: normal calcium (2.39 mmol/L, 95% CI 2.36  W 2.42) with low 
PTH (10.1 ng/L, 95% CI 9.2  W 11.1). 
 
- 12 subjects (0.5%) affected by non-PTH hypercalcaemia: high calcium (2.82 mmol/259 L, 95% CI 
2.75  W 2.89) with low or low normal PTH (18.5 ng/L, 95% CI 16.2  W 21.3). 
 
Normocalcemic hypoparathyroidism 
There are statistically significant differences if we compare the NHYPO group with the normal group 
in 264 terms of BAP (difference = -15.4%, 95% CI: -26.2 to -3.0, p=0.007), CTX (difference = -66.3%, 
95% CI: -74.0 to -56.4, p<0.001) and osteocalcin (difference = -36.8%, 95% CI: -45.6 to -26.6, 
p<0.001). Baseline BMD parameters and the lumbar spine and hip change over the time have not 
been shown any statistically significant differences compared to the normal group. At the second 
visit (after 6 years), of the 35 NHYPO subjects with follow-up data, none developed overt 
hypoparathyroidism and only 15 (0.6%) subjects had persistent evidence of NHYPO. 
 
Comparisons between the different categories and normal subjects (Tables 3,4) 
At baseline, no statistically significant differences have been found between the different groups 
compared to the normal subjects with regards to age, BMI and lumbar spine BMD. According to its 
definition, secondary hyperparathyroidism has been shown a statistically significant difference in 
terms of 25 (OH) vitamin D and eGFR compared to the normal group (respectively, difference = -
15.9%, 95% CI: -27.2 to -2.8, p=0.011. Difference = -16.0%, 95% CI: -21.8 to -9.8, p<0.001). In subjects 
with HH and non-PTH hypercalcaemia there is a statistically significant reduction in terms of eGFR 
compared to the normal group (respectively, difference = -11.7%, 95% CI: -17.4 to -5.7, p<0.001; 
Difference = -17.0%, 95% CI: -30.3 to -1.2, p=0.024). 
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Bone metabolic parameters 
BMD 
At baseline, no statistically significant differences have been found between the different groups 
compared to normal subjects at the lumbar spine. Post-hoc testing has been demonstrated a 
statistically significant difference in the mean hip T-Score between the normal group and the 
secondary hyperparathyroidism group (difference = -0.47, 95% CI: -0.83 to -0.11, p=0.004). The 
lumbar spine and hip BMD change over the time (rate of bone loss per year from the baseline) did 
not show any statistically significant differences between abnormal calcaemia categories compared 
to the normal group. The baseline total hip BMD is inversely related to serum PTH (R= -0.006, 
p<0.001), age (R= -0.058, p<0.001). It is also positively related to BMI (R= 0.105, p<0.001). The 
change in total hip BMD is inversely related to serum calcium (R= -27.567, p<0.001) and age (R= -
0.425, p=0.029) (Table 5). 
 
Bone turnover markers (table 4) 
CTX 
We found a statistically significant difference between the normal group and the HH 294 PHPT 
(difference = 24.0%, 95% CI: 1.5 to 51.3, p=0.0249), secondary hyperparathyroidism (difference = 
28.1%, 95% CI: 2.8 to 59.5, p=0.020) and non-PTH hypercalcaemia (difference = -54.6%, 95% CI: -73.2 
to -23.3, p=0.001). 
 
Osteocalcin 
We found a statistically significant difference between the normal group and secondary 
hyperparathyroidism (difference = 35.6%, 95% CI: 18.0 to 55.9, p<0.001). 
 
Bone ALP 
We found a statistically significant difference between the normal group and non-PTH 
hypercalcaemia group (difference = -27.2%, 95% CI: -45.80 to -2.3, p=0.023). 
 
PINP 
There were no statistically significant differences when we compared the normal group to the other 
different categories. 
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Stability of PTH over time 
In the overall population there is a statistically significant change in PTH measurement from 
baseline. The mean PTH measurement increased from 41.6 (SD = 21.1) at baseline to 45.5 (SD = 26.1) 
at six years (mean change = 3.9, 95% CI: 2.79 to 4.98, P<0.001). 
 
Discussion 
This is the first study that has investigated the prevalence of NHYPO in a large cohort of 
postmenopausal women. Cusano et al have previously conducted a large trial to evaluate the 
epidemiology of these subclinical conditions in an unselected community-based sample of old men 
(The Osteoporotic Fractures in Men study, MrOS study) and young men with premenopausal women 
(Dallas Heart Study, DHS) revealing a prevalence respectively of 0.4% and 3.1% for NPHPT and of 
1.1% and 1.9% respectively for NHYPO (4). At baseline we identified 57 subjects (2.4%) affected by 
NHYPO and just 1 subject (0.1%) affected by normal hyperparathyroidism after ruling out the main 
causes of secondary hyperparathyroidism (vitamin D deficiency, eGFR < 60 ml/min and only 6 
NHYPO subjects were taking proton pump inhibitors). In our cohort the prevalence of NHYPO is 
higher in comparison with the previous study: this is probably due to the differences in gender and 
age between the three populations. 
 
Even if the baseline cross-sectional data indicate the existence of the NHYPO as a new subclinical 
pathological category, the longitudinal data give rise to many doubts. Indeed at the 6 years visit, of 
the 35 NHYPO subjects with follow-up data, none of them developed overt hypoparathyroidism and 
only 15 (0.6%) out of 35 subjects had persistent evidence of NHYPO. This finding is in keeping with 
that reported by others; Cusano and colleagues identified 68 subjects with NHYPO, none of whom 
developed overt hypoparathyroidism on follow-up and persistent disease was noted in 2 of 26 
subjects with follow-up (4). 
 
A few studies have shown that bone turnover marker levels are frankly low or low-normal in patients 
with hypoparathyroidism compared to normal subjects (17-20) and these findings are consistent 
with histomorphometric analysis. In particular double-tetracycline labelling of bone biopsy 
specimens have demonstrated that dynamic skeletal indices are suppressed in hypoparathyroid 
patients (21). According to ƚŚĞƐĞƉƌĞǀŝŽƵƐĚĂƚĂ ?E,zWKƐĞĞŵƐƚŽďĞĐŚĂƌĂĐƚĞƌŝǌĞĚďǇĂ “ůŽǁďŽŶĞ
turnŽǀĞƌ ?ǁŝƚŚŽƵƚĂƐŝŐŶŝĨŝcant BMD change over the time compared to the normal group. Indeed, 
we found a significant reduction in serum levels of CTX, BAP and osteocalcin compared to subjects 
with no impairment of calcium metabolism. 
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Once again these findings confirm the key role of PTH in the bone metabolism: a few studies have 
demonstrated that daily subcutaneous injections of PTH (1-84) result in a significant increase of 
bone formation and resorption markers (that were suppressed at baseline) in patients affected by 
hypoparathyroidism (22).  
 
Our data on NHYPO raise questions on the appropriate management of thiƐĐĂƚĞŐŽƌǇ ?WƌŽďĂďůǇƚŚĞ “
wait ĂŶĚƐĞĞƚŚĞŽƌǇ ?ĐŽƵůĚďĞƚŚĞŵŽƐƚƐƵŝƚĂďůĞ ?We don't have sufficient data for recommendations 
for these 345 subjects. Anyway if the patients take a medication that might induce hypocalcemia, 
such as an anti-resorptive drug (such as bisphosphonate, denosumab) or a loop-acting diuretic (such 
as furosemide) then monitoring of serum calcium is to be recommended. Therefore the potential 
choice of the treatment for subjects with NHYPO affected by osteoporosis is critical. Indeed powerful 
anti-resorptive drugs such as bisphosphonates and denosumab, could exacerbate the risk of 
adynamic bone disease by suppressing the bone turnover (23). Conversely, anabolic therapy could 
restore the physiological bone turnover (24) but we are not able to predict if patients with NHYPO 
will experience an improvement in BMD. Indeed, in contrast to the effect of PTH (1 W84) treatment in 
patients with osteoporosis, PTH (1-84) replacement therapy causes a general decrease in BMD at the 
hip, lumbar spine and whole body (apart from the forearm) in subjects with hypoparathyroidism 
(22). Despite the significant changes in bone turnover, teriparatide did not provide any significant 
BMD improvement in hypoparathyroidism (20). In particular, after 3 years of twice daily PTH (1 W34) 
treatment, BMD and bone mineral content (BMC) at the lumbar spine, femoral neck, and whole 
body maintained stable although there was a non-significant downward trend in the distal one-third 
radius BMD. 
 
It was noteworthy that the prevalence of PHPT was so high. The biochemical abnormality of high 
serum calcium and high or high-normal PTH is also found in familial hypocalciuric hypercalcemia but 
we did not conduct any calcium excretion studies or gene testing to role out it. Most our cases were 
mild and the mean PTH was only at the upper limit of the reference interval for PTH; this might 
explain why most bone turnover markers were normal. The diagnosis of hypercalcaemia was made 
on samples after the second visit so it did not influence clinical management during the follow-up 
period. 
 
It was also surprising that our rate of NPHPT was lower than in the MrOS as many epidemiological 
studies have confirmed that hyperparathyroidism is less frequent in men(25, 26). Other large 
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retrospective studies have attempted to evaluate the epidemiology of NPHPT but most have not 
ruled out the main causes of secondary hyperparathyroidism (27-29). Probably the low prevalence 
of NPHPT in our population may be explained by the high rate of vitamin D insufficiency (52.3%, data 
not shown) and eGFR reduction (62.4 %, data not shown); the former due to geographical 
differences and that latter due to the higher mean age in cŽŵƉĂƌŝƐŽŶƚŽƵƐĂŶŽ ?ƐƉŽƉƵůĂƚŝŽŶƐ ?
Probably the current definition of NPHPT tends to underestimate the prevalence of this category. 
Indeed according the data published by Shibli-Rahhal (30), in our population only 10.7% (data not 
shown) of older women with 25OHD < 20 ng/ml had an elevated PTH. 
 
However, circulating PTH concentrations display a large inter-individual variability: calcium intake, 
some drugs such as lithium, MgSO4, diuretics etc. are able to affect the PTH serum levels. Moreover 
this variance has been demonstrated to have a strong hereditable component (1) but the genetic 
factors governing serum PTH concentrations remain unknown. Indeed, although it is well 
documented that loss of function and gain of function mutations of the CaSR lead respectively to 
hypercalcemic and hypocalcemic disorders (31), no studies aimed to assess the status of CaSR in 
NPHPT and hypoparathyroidism subjects. Another interesting area of research could be the 
evaluation of the autoantibodies directed against the extracellular domain of the CaSR and NALP5 in 
subjects with NHYPO. Previous studies have identified the CaSR and NALP5 as parathyroid 
autoantibody targets in patients with autoimmune polyendocrinopathy-candidiasis ectodermal 
dystrophy (32) or in subjects with autoimmune hypocalciuric hypercalcemia (33-35) but it is unclear 
whether these antibodies may also contribute to the variability in serum PTH concentrations 
observed in normocalcaemic individuals. 
 
KƵƌƐƚƵĚǇŚĂƐĂĨĞǁůŝŵŝƚĂƚŝŽŶƐ ?tĞĚŝĚŶ ?ƚŵĞĂƐƵƌĞŝŽŶŝǌĞĚĐĂůcium and fĂƐƚŝŶŐƉŚŽƐƉŚĂƚĞ ?ǁĞĚŽŶ ?ƚ
have any biochemical data between the first visit at baseline and the second visit at 6 years later, we 
have only a single value for each laboratory analyte at each time point, we lost a significant number 
of subjects over the course of the study and BMD analysis was performed by two different 
instruments. Moreover the prevalence of the different diagnostic categories might be affected by 
long-term PTH storage. Anyway we do not think that relatively high prevalence of NHYPO could be 
attributable to degradation of PTH during storage. Indeed it has been estimated by some authors 
that there is about a 1% increase in intact PTH every year in women, with an faster rise after the 
menopause (36,37); therefore the 9% increase we observed is likely to be age-related rather than 
resulting from minor degradation. Moreover if the low prevalence of SHPT and relatively high 
prevalence of NHYPO had been attributable to degradation of PTH during storage, we would have 
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expected also a low prevalence of hyperparathyroid hypercalcemia (PHPT and FHH). Instead we have 
a high prevalence of hyperparathyroid hypercalcemia. 
 
/ŶĐŽŵƉĂƌŝƐŽŶƚŽƵƐĂŶŽ ?ƐĨŝŶĚŝŶŐƐ ?ƚŚĞƉƌĞǀĂůĞŶĐĞŽĨ^,WdǁĂƐƋƵŝƚĞlow. This could be explained 
by the higher dietary calcium intake found in European countries compared to the US population. In 
one review, the mean calcium intake in the NHANES III study in older women 402 was 600 mg/day, 
considerable lower than the estimates for UK (800 mg), France (850 mg) and Germany (970 mg) (38). 
This is the first large population based study that has investigated the prevalence and the bone 
metabolic status of NPHPT in postmenopausal women: it is fairly common, not always persistent and 
is characterized by low bone turnover. 
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Figure 1. Baseline data results for adjusted calcium and PTH. The ellipse was derived using 
Mahalanobis distances method to define normal (black) and abnormal (red) values.  The horizontal 
and vertical lines indicate the geometric mean, and reference intervals described in Table 1. The pink 
rectangle identifies subjects with normocalcemic hypoparathyroidism. 
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Figure 2. Follow-up results for adjusted calcium and PTH. The ellipse was derived using Mahalanobis 
distances method to define normal (black) and abnormal (red) values. The horizontal and vertical 
lines indicate the geometric mean, and reference intervals obtained from the healthy young women.  
The pink rectangle identifies subjects with normocalcemic hypoparathyroidism. 
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Table 1. Reference Intervals for Adjusted Calcium and PTH Healthy Young Women. 
 Geometric 
Mean 
Reference 
Range 
95% CI of lower 
limit of 
reference range 
95% CI of upper 
limit of reference 
range 
Mean (SD) 
log10 
Adjusted Serum 
Calcium 
(mmol/L) 
(N = 107) 
2.359 2.123  W 2.620 2.086  W 2.160 2.575  W 2.667 0.373 
(0.023) 
PTH 
(ng/L) 
(N=107) 
25.707 10.937  W 60.419 9.493  W 12.602 52.441  W 69.612 1.410 
(0.189) 
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Table 2a. Baseline characteristics of the older and younger women in the OPUS study 
 Premenopausal Postmenopausal 
 N Mean SD N Mean SD 
Age (years) 463 31.3 5.5 2419 67.1 7.1 
Height (cm) 463 166.0 6.7 2418 160.3 6.3 
Weight (kg) 463 66.3 13.0 2418 68.7 12.3 
BMI (kg/m²) 463 24.0 4.4 2418 26.7 4.5 
Lumbar Spine BMD T-Score 462 0.09 1.12 2372 -0.94 1.51 
Total Hip BMD T-Score 462 0.27 1.01 2396 -0.64 1.16 
CTX (ng/mL) 423 0.25 0.17 2287 0.36 0.27 
PINP (ng/mL) 435 39.7 20.6 2260 42.5 22.0 
Bone ALP (ng/mL) 441 11.5 5.1 2313 15.1 6.4 
Osteocalcin (ng/mL) 441 21.2 8.0 2303 24.5 13.9 
25 (OH) Vitamin D (ng/mL) 440 25.4 12.6 2311 21.3 10.3 
eGFR (mL/minute/1.73m²) 439 86.1 12.3 2317 57.5 13.5 
Calcium (mmol/L) 440 2.37 0.13 2320 2.39 0.16 
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Table 2b. Baseline characteristics for normal and NHYPO subjects 
 Age 
(years) 
BMI 
(Kg/m²) 
Spine 
T-Score 
Hip 
T-Score 
 N Mean 
(95% CI) 
N Mean 
(95% CI) 
N Mean 
(95% CI) 
N Mean 
(95% CI) 
Normal 2063 67.0 
(66.7, 67.3) 
2062 26.6 
(26.5, 26.8) 
2024 -0.95 
(-1.01, -0.88) 
2043 -0.64 
(-0.69, 0.59) 
Normocalcaemic 
Hypoparathyroidism 
57 66.3 
(64.6, 67.9) 
57 26.2 
(25.1, 27.3) 
57 -0.64 
(-1.07, 0.21) 
57 -0.47 
(-0.78, -0.16) 
P-Value
a
 
 
ns ns ns ns 
a P-Value from ANOVA testing for an overall difference in means 
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Table 3. Baseline calcium metabolism characteristics for each category. 
 Adjusted Calcium 
(mmol/L) 
PTH 
(ng/L) 
25(OH)D 
(ng/ml) 
eGFR 
(ml/min) 
 N Geometric  
Mean  
(95% CI) 
N Geometric  
Mean  
(95% CI) 
N Geometric  
Mean  
(95% CI) 
N Geometric  
Mean  
(95% CI) 
Normal 
 
2063 2.40 
(2.39, 2.41) 
2063 39.0 
(38.4, 39.7) 
2058 19.2 
(18.9, 19.6) 
2060 56.7 
(56.1, 57.2) 
Primary 
Hyperparathyroidism 
86 2.79*** 
(2.78, 2.80) 
86 58.8*** 
(52.6, 65.8) 
85 17.9 
(16.1, 19.9) 
85 50.0*** 
(47.8, 52.2) 
Secondary 
Hyperparathyroidism 
69 2.16*** 
(2.09, 2.23) 
69 88.9*** 
(75.8, 104.3) 
69 16.2* 
(14.1, 18.6) 
69 47.6*** 
(44.1, 51.3) 
Normocalcaemic 
Hypoparathyroidism 
57 2.39 
(2.36, 2.42) 
57 10.1*** 
(9.2, 11.1) 
57 20.7 
(18.0, 23.8) 
57 53.0 
(50.3, 55.9) 
Non-PTH 
Hypercalcaemia 
12 2.82*** 
(2.75, 2.89) 
12 18.6*** 
(16.2, 21.3) 
12 19.9 
(15.1, 26.2) 
12 47.0* 
(40.8, 54.2) 
P-Value
a
 
 
<0.001 <0.001 0.015 <0.001 
a
P-Value from ANOVA testing for an overall difference in means 
Post-hoc testing for a difference in mean from the Normal group: * P-Value <0.050, ** P-Value < 
0.010, *** P-Value < 0.001 
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Table 4. Baseline bone turnover markers for each category. 
 PINP 
(ng/mL) 
BAP 
(ng/mL) 
CTX 
(ng/mL) 
OC 
(ng/mL) 
 N Geometric  
Mean  
(95% CI) 
N Geometric  
Mean  
(95% CI) 
N Geometric  
Mean  
(95% CI) 
N Geometric  
Mean  
(95% CI) 
Normal 
 
2013 36.7 
(35.7, 37.6) 
2061 14.0 
(13.7, 14.2) 
2046 0.29 
(0.28, 0.30) 
2032 22.1 
(21.7, 22.5) 
Primary 
Hyperparathyroidism 
85 41.0 
(35.9, 46.9) 
86 14.8 
(13.4, 16.3) 
86 0.35* 
(0.30, 0.41) 
85 24.2 
(21.1, 27.7) 
Secondary 
Hyperparathyroidism 
69 39.8 
(33.9, 46.7) 
69 14.7 
(12.8, 17.0) 
67 0.36* 
(0.29, 0.45) 
63 30.0*** 
(25.4, 35.5) 
Normocalcaemic 
Hypoparathyroidism 
55 31.0 
(26.6, 36.3) 
57 11.8** 
(10.5, 13.3) 
50 0.10*** 
(0.07, 0.13) 
57 14.0*** 
(12.3, 16.0) 
Non-PTH 
Hypercalcaemia 
11 30.6 
(20.7, 45.1) 
12 10.2* 
(6.1, 16.8) 
12 0.13*** 
(0.07, 0.24) 
12 16.3 
(13.3, 20.1) 
P-Value
a
 
 
0.048 <0.001 <0.001 <0.001 
aP-Value from ANOVA testing for an overall difference in means 
Post-hoc testing for a difference in mean from the Normal group: * P-Value <0.050, ** P-Value < 
0.010, *** P-Value < 0.001 
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Table 5a. Multiple regression analysis  W do baseline measurements predict baseline BMD? 
Hip T-Score at Baseline = Intercept + Calcium + PTH + Age + BMI 
 Coefficient 95% CI P-Value 
Adjusted Calcium 0.277 (0.017, 0.537) 0.037 
PTH -0.006 (-0.007, -0.004) <0.001 
Age -0.058 (-0.063, -0.052) <0.001 
BMI 0.105 (0.096, 0.114) <0.001 
Values are per unit increase 
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Table 5b. Multiple regression analysis  W do baseline measurements predict change in BMD? 
Change in Hip BMD = Intercept + Baseline BMD + Calcium + PTH + Age +BMI 
 Coefficient 95% CI P-Value 
Baseline Hip BMD -0.095 (-0.116, -0.075) <0.001 
Adjusted Calcium -27.567 (-43.318, -11.815) 0.001 
PTH -0.081 (-0.195, 0.033) 0.164 
Age -0.425 (-0.806, -0.044) 0.029 
BMI 0.455 (-0.140, 1.049) 0.134 
 
 
 
 
 
 
 
 
